Since 1923, we have consistently devised and developed major advances for the treatment of allergy. In recent years, together with our global partners, we have invested substantially in the research and development of new, evidence-based allergy immunotherapy treatments.
We have has entered into partnership agreements with Torii, Abbott and Seqirus to commercialise allergy immunotherapy tablets in Japan, Russia and South-East Asia, and Australia and New Zealand, respectively.
As of June 2016, the Lundbeck Foundation is the largest and controlling shareholder of ALK, owning 67% of the votes (40% of the capital). The foundation’s uses the return on its investment in ALK to contribute to society.